Windward Bio
10 known investors
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.
BiotechHealthtech
Investors · 10
OrbiMedNew York · $1M – $75M
Quan CapitalShanghai
RA CapitalBoston
Sanofi VenturesCambridge · $5M
SR One Capital ManagementRedwood City
Janus Henderson InvestorsreportedNew York
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Pivotal Life SciencesreportedSan Francisco
Qiming Venture PartnersreportedBeijing · $5M – $134M
RTW Investments L.P.reportedNew York
Funding
SEC filings, press & company announcements- Undisclosed amountCrossoverMay 2026Source ↗
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Windward Bio do?
- Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.
- Who are Windward Bio's investors?
- Windward Bio's investors include OrbiMed, Quan Capital, RA Capital, Sanofi Ventures, SR One Capital Management, Janus Henderson Investors, Novo Holdings, Pivotal Life Sciences and 2 more.